Protocol Ledger

NCT05180097 · Phase II · RECRUITING

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Interventional Phase II clinical trial protocol NCT05180097 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-01 Enrollment: 84 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05180097
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)84 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05180097
Protocol FieldVerified Registry Value
NCT IdentifierNCT05180097
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment84 participants (ESTIMATED)
Registered Start Date2022-11-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05180097
Hospital Research SiteLocationSite Profile
Concord Repatriation General HospitalConcord, AustraliaOpen Hospital Dossier ->
Royal Adelaide HospitalAdelaide, AustraliaOpen Hospital Dossier ->
Austin HospitalHeidelberg, AustraliaOpen Hospital Dossier ->
Arthur J E Child Comprehensive Cancer CentreCalgary, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI